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Abstract
In T lymphocytes, p38 MAP kinase (MAPK) regulates pleiotropic functions and is activated by 
canonical MAPK signaling or the alternative T cell receptor (TCR) activation pathway. Here we 
show that senescent human T cells lack the canonical and alternative pathways of p38 activation, 
but spontaneously engage the metabolic master regulator AMPK to trigger p38 recruitment to the 
scaffold TAB1 causing p38 auto-phosphorylation. Signaling via this pathway inhibits telomerase 
activity, T cell proliferation and expression of key components of the TCR signalosome. Our 
findings identify an unrecognized mode of p38 activation in T cells driven by intracellular changes 
such as low-nutrient and DNA-damage signaling (‘intra-sensory’ pathway). The proliferative 
defect of senescent T cells is reversed by blocking AMPK-TAB1-dependent p38 activation.
Introduction
T cell proliferative responses are essential for the lifelong preservation of adaptive 
immunity. Optimal T cell activation requires both T cell receptor (TCR) engagement and co-
stimulatory signals1 however progressive loss of CD27 and CD28 co-stimulatory receptors 
occurs during end-stage T cell differentiation towards senescence that correlates well with a 
loss of proliferation2. The mechanisms that regulate the loss of proliferative potential in 
highly differentiated T cells are poorly understood. The aim of this study is to identify 
mechanisms involved in human end-stage T cell differentiation and whether intervention is 
possible to restore proliferative activity in these cells.
The loss of surface CD27, followed by loss of CD28 expression during human CD4+ T cell 
differentiation3 enables the identification of undifferentiated T cells that have high 
proliferative activity and the longest telomeres (CD27+ CD28+); intermediate differentiated 
cells that have reduced proliferation and telomeres of intermediate length (CD27− CD28+) 
and end-stage or senescent T cells that proliferate poorly and have the shortest telomeres 
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(CD27− CD28−)3. Senescent CD27− CD28− CD4+ T lymphocytes accumulate significantly 
in old humans, in patients with chronic viral infections and in those with autoimmune 
disorders3-7. The senescence characteristics of these cells include short telomeres, low 
telomerase activity and reduced proliferative capability8 that is due in part to a spontaneous 
but unexplained increase in p38 MAPK activity9. Nevertheless CD27− CD28− CD4+ T cells 
exhibit potent effector functions and cannot be viewed as a dysfunctional population per 
se3-7. Here we investigated the regulatory network upstream of p38 MAPK in the senescent 
CD27− CD28− CD4+ T cell subset. The p38 MAPK family comprises α, β, γ and δ isoforms 
that regulate a number of different functions in a cell-type and stimulus dependent manner10. 
T lymphocytes mainly express the α and to a lesser extent the β and δ isoforms of p3810. 
The canonical MAPK cascade is the main mechanism for activation of all four p38 isoforms 
in mammalian cells, including T cells10-12. Signaling through the MAPK pathway activates 
p38 by dual phosphorylation on Thr180 and Tyr182 sites in response to environmental stress, 
inflammation, DNA damage12 and also co-stimulatory receptor engagement13. In addition, 
T cells have an alternative pathway of p38 activation, in which antigenic stimulation via the 
T cell receptor (TCR) induces p38α and β phosphorylation on Tyr323 by TCR-proximal 
tyrosine kinases14, followed by auto-phosphorylation on Thr180 and Tyr182 (14).
We now demonstrate that instead of using the canonical or the alternative pathways, freshly 
isolated CD27− CD28− CD4+ T lymphocytes engage a distinct mechanism whereby the 
intracellular metabolic sensor AMPK triggers p38 auto-phosphorylation via the scaffold 
protein TAB1. Furthermore, signaling through this pathway down-regulates central 
components of the TCR signalosome, a previously unidentified characteristic of T cell 
senescence. Activation of p38 through AMPK-TAB1 can be induced by both endogenous 
DNA damage but also by a fall of intracellular energy levels. Thus, unlike the canonical and 
alternative pathways for p38 activation that respond to external cues (e.g. cytokines or TCR 
activation), T cells have an ‘intra-sensory’ pathway for p38 activation that senses 
intracellular changes such as glucose deprivation and genotoxic stress. Once triggered, this 
pathway inhibits T cell proliferation and telomerase activation via p38 MAPK signaling and 
this can be reversed by inhibiting AMPK, TAB1 or p38 itself.
Results
p38 activation in the absence of canonical and alternative pathways
The relative expression of CD27 and CD28 receptors identifies three distinct populations in 
primary human CD4+ T cells (Fig. 1a). CD27− CD28− T cells are known to exhibit low 
telomerase and proliferative activity upon activation3, which are characteristics of end-stage 
differentiation or senescence3, 4, 9, 15. The CD27− CD28-subset of CD4+ T cells also 
exhibits endogenously elevated p38 (Thr180 and Tyr182) phosphorylation that is significantly 
higher than CD27+ CD28+ or CD27− CD28+ T cell subsets in vivo (by 2-2.5 fold, p< 0.001; 
Fig. 1b).
We investigated whether the canonical MAPK cascade, which regulates p38 activation in 
response to stress stimuli and co-stimulatory receptor engagement12, 13 was responsible for 
the endogenous p38 activation observed in CD27− CD28− CD4+ T cells. Freshly isolated 
human CD27− CD28− CD4+ T cells did not express nor activate either MKK3 or MKK6 
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(Fig. 1c,d), the direct upstream regulators of p38 in this signaling cascade12. Similarly, these 
cells did not activate MKK4 (data not shown), an activator of the MAP kinase JNK16 which 
in some instances may also activate p38 (ref 10). Furthermore, phorbol 12-myristate 13-
acetate (PMA), a well-established agonist of canonical MAPK cascade17, failed to enhance 
p38 activity in CD27− CD28-CD4+ T cells, while inducing a significant increase of p38 
phosphorylation in the undifferentiated CD27+ CD28+ subset (p< 0.001; Fig. 1e,f). Similar 
observations were made when inducing the p38 canonical pathway by an osmotic stressor 
(sorbitol, data not shown). Thus, despite the constitutive increase in p38 activity (Fig. 1b), 
human senescent CD27− CD28− CD4+ T cells do not regulate p38 signaling by the 
canonical MAPK cascade.
Antigenic stimulation through the TCR activates p38 by an alternative pathway where a 
protein tyrosine kinase (PTK) cascade that is dependent on LCK and mediated by ZAP-70, 
phosphorylates p38 at Tyr323 (ref 14). The membrane-associated scaffold molecule DLG1 
binds p38 and coordinates this process18. Because persistent antigenic stimulation drives 
human T cell differentiation in vivo2, 3, we tested if the alternative pathway of p38 activation 
through TCR signaling was responsible for inducing p38 signaling in CD27− CD28− CD4+ 
T cells. However, we found that the CD27− CD28− CD4+ population did not phosphorylate 
p38 on the alternative Tyr323 site either before or after anti-(α)CD3 stimulation (Fig. 1g). In 
contrast, undifferentiated CD27+ CD28+ CD4+ T cells expressed high levels of 
phosphorylated p38 (Tyr323) upon CD3 activation (Fig. 1g).
We next investigated the expression of the elements of the TCR signalosome that constitute 
the alternative pathway of p38 activation in CD27+ CD28+ , CD27− CD28+ and CD27− 
CD28− CD4+ T cells. We found that freshly isolated CD27− CD28− CD4+ T cells did not 
express Lck, Zap70 and DLG1 in contrast to the CD27+ CD28+ and CD27− CD28+ CD4+ 
subsets (Fig. 1h,i). In addition, these cells also lacked other essential downstream 
components of the TCR signaling machinery, such as the adaptors Lat and SLP-76 and had 
very low expression of the phospholipase PLC-γ1 (Supplementary Fig. 1a,b). The loss of 
TCR signaling machinery in senescent CD27− CD28− CD4+ T cells was also associated 
with defective calcium influx upon αCD3 stimulation, indicating that the loss of TCR 
signaling molecules impaired TCR responsiveness (Supplementary Fig. 1c,d). Taken 
together, these data indicate that the spontaneous increase of p38 activity observed in CD27− 
CD28− CD4+ T cells is not regulated by either the canonical MKK or alternative TCR 
mediated signaling pathways, in contrast to p38 regulation in non-senescent CD4+ T 
cells 11, 19.
p38 activation is triggered by AMPK and mediated by TAB1
In human embryonic kidney (HEK) 293-cells, allosteric p38 (Thr180 and Tyr182) auto-
phosphorylation is induced independently of upstream MKKs via the scaffold molecule 
TAB120. We investigated whether TAB1 signaling was involved in the constitutive p38 
activation observed in senescent CD27− CD28− CD4+ T cells. Two TAB1 splicing-variants 
(α or β), of 60-kDa and 50-kDa, bind to and activate p38 by an identical mechanism21. 
Using a monoclonal antibody directed against the p38-binding domain common to both 
isoforms, we found that CD27− CD28− CD4+ T cells expressed the 50-kDa isoform of 
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TAB1 (Fig. 2a), which does not bind to nor regulate TAK121. In addition CD27− CD28− 
CD4+ T cells also did not express TAK1 itself (Fig. 2a). Conversely, non-senescent T cell 
subsets expressed TAK1 and also the full length TAB1, which binds to TAK1 (Fig. 2a). 
Because the activation of the TAB1 pathway requires non-degradative ubiquitination by the 
upstream E3 ubiquitin-ligase TRAF620, we examined the expression of TRAF6 in the non-
senescent and senescent CD4+ T cell subsets. CD27− CD28− CD4+ T cells lacked TRAF6 
expression (Fig 2a), indicating that the TRAF6-TAK1 pathway is not active in these cells.
AMPK, is activated in response to low intracellular levels of glucose and has been shown to 
bind to TAB1 in mouse ischemic cardiomyocytes22. This molecule is activated by 
phosphorylation on Thr172 in its catalytic α-subunit to shift metabolism towards catabolic 
reactions23. In addition, AMPK inhibits mTOR activity in T cells24,25. We investigated 
whether AMPK regulates p38 activity in CD27− CD28-CD4+ T cells through TAB1. 
Freshly isolated human CD27+ CD28+, CD27− CD28+ and CD27− CD28− CD4+ T cells all 
expressed AMPKα, but only the CD27− CD28-CD4+ T cell subset showed spontaneous 
AMPKα activation (p-AMPKα; Fig. 2b). To determine whether AMPK was acting upstream 
of p38 in T cells, we treated CD27+ CD28+ CD4+ T cells, that have no base-line AMPK 
activity (Fig. 2b) and exhibit low spontaneous p38 phosphorylation (Fig. 1b), with the 
selective AMPK agonist A-76966226. The agonist induced significant p38 (Thr180 and 
Tyr182) phosphorylation in CD27+ CD28+ CD4+ T cells (p<0.01; Fig. 2c,d). Despite their 
high baseline p38 activity, A-769662 also enhanced p38 (Thr180/Tyr182) phosphorylation in 
senescent CD27− CD28− CD4+ T cells (data not shown).
To directly investigate the role of TAB1 and AMPK signaling on p38 activation, we used 
VSV-g pseudo-typed lentiviral vectors co-expressing a GFP reporter gene and short-hairpin 
(sh) RNAs silencing either the catalytic α subunit of AMPK (shAMPKα) or a region 
common to both the 60 and 50-kDa isoforms of TAB1 (shTAB1) (Supplementary Fig. 2a-d). 
An irrelevant, scrambled hairpin expressing vector (shCtrl) was used as control 
(Supplementary Fig. 2c,d). Isolated CD27− CD28-CD4+ T cells were transduced with these 
vectors 48 hours after activation with αCD3 and rh-IL-2. Four days post-transduction, we 
examined changes in p38 phosphorylation (Thr180 and Tyr182) in GFP+ T cells by phospho-
flow analysis (Fig. 2e). Under steady-state conditions, both AMPKα and TAB1-silenced 
GFP+ T cells showed a significant inhibition of p38 activity compared to scrambled control 
vector (p<0.01; Fig. 2e), indicating that AMPK and TAB1 regulate p38 activation in human 
senescent CD4+ T cells.
We next treated the shAMPKα transduced CD27− CD28− CD4+ T cells with the AMPK 
agonist A-769662 for 1 hour followed immediately by phospho-flow analysis of p38 
activation in the GFP+ T cells (Fig. 2f,g). The AMPK agonist-induced activation of p38 was 
inhibited in the CD27− CD28− CD4+ T cells confirming that the process was AMPK 
dependent (Fig. 2f,g). The AMPK agonist-induced p38 activation was also inhibited in 
TAB1-silenced CD4+ CD27− CD28− T cells (Fig. 2h,i), indicating that AMPK requires 
TAB1 to activate p38 in these cells. Silencing of either AMPKα or TAB1 in AMPK agonist-
activated CD27− CD28− CD4+ T cells also inhibited phosphorylation of the p38 substrate 
ATF2 (at residue Thr71) (Fig. 2h,i). Similarly, agonist–driven AMPK activation failed to 
activate p38 in AMPK and TAB1-silenced CD27+ CD28+ CD4+ T cells (data not shown). 
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Thus, AMPK activation induces p38 MAPK signaling in a TAB1-dependent way in 
senescent human CD4+ T cells.
DNA damage and low-nutrient sensing by AMPK activates p38
Cellular AMPK is mainly activated in response to decreased intracellular ATP23. However, 
we did not find a reduction of cellular ATP levels in freshly isolated senescent human 
CD27− CD28− CD4+ T cells compared to the CD27+ CD28+ and CD27+ CD28− subsets 
(data not shown). Because only end-stage differentiated CD27-CD28− CD4+ T cells 
exhibited spontaneous AMPK activity, we investigated whether various end-stage 
differentiation features of these cells triggered AMPK activation. We found evidence of 
endogenous DNA damage27 in CD27− CD28− CD4+ T cells, including spontaneous 
phosphorylation of the DDR apical kinase ATM (Ser1921) (Fig. 3a,b) and of its downstream 
target H2A-X (Ser139) (Fig. 3c,d) , which have been previously used as indicators of active 
DNA damage foci28. Inhibition of ATM activity by the selective ATM inhibitor KU-55933 
for 1 hour inhibited constitutive AMPKα (Thr172) and p38 (Thr180-Tyr182) phosphorylation 
in CD27− CD28− CD4+ T cells (Fig. 3e-h), indicating that ATM acted ‘upstream’ of both 
molecules in these cells. We also found elevated reactive oxidative species (ROS) 
expression in these cells (Supplementary Fig. 3a). Because genotoxic stress by ROS induces 
DNA damage29 and because ROS are a known activator of AMPK30, we tested the effect of 
the ROS scavenger superoxide-dismutase (SOD) on ATM, AMPK and p38 activation. ROS 
scavenging impaired activation of all three molecules in CD27− CD28− CD4+ T cells 
(Supplementary Fig. 3b,c), suggesting that ROS may be triggering the endogenous DNA 
damage response leading to p38 activation in human senescent T cells.
Because AMPK acts as a low-glucose sensor in cells23, 24, we tested if glucose deprivation 
also induced AMPK-dependent p38 activation in non-senescent T cells that have intact 
DNA and low ROS production (Fig. 3a-d and Supplementary Fig. 3a). Glucose starvation of 
undifferentiated CD27+ CD28+ CD4+ T cells enhanced p38 phosphorylation (Fig. 3i,j). 
Silencing of either AMPK or TAB1 effectively inhibited p38 phosphorylation following 
glucose deprivation in these cells compared to scrambled control transduced cells (Fig. 3k,l). 
Taken together, these data support a model where signals from both genotoxic and nutrient 
sensing pathways converge at the point of AMPK in T cells, which subsequently activates 
p38 through the scaffold molecule TAB1.
AMPK triggered p38 recruitment to TAB1 causes p38 auto-phosphorylation
To further dissect the mechanistic details of the AMPK-TAB1-p38 pathway, we performed 
immunoprecipitation studies in primary human CD27+ CD28+ CD4+ T cells activated by the 
AMPK agonist (A-769662). Immunoblot analysis of TAB1 immunoprecipitates from these 
cells showed that agonist-driven AMPK activation promoted p38 recruitment to TAB1 (by 
2.5-3 fold, Fig. 4a,b). Furthermore, TAB1 immunoprecipitates were specifically enriched for 
both phosphorylated AMPK and p38 (Fig. 4a), suggesting the existence of an active AMPK-
TAB1-p38 complex. Similarly, TAB1 immunoprecipitates from glucose-starved 
undifferentiated CD27+ CD28+ CD4+ T cells were also enriched for both phosphorylated 
AMPK and p38 (data not shown). Importantly, activated AMPK and p38 were constitutively 
present in TAB1 immunoprecipitates from CD27− CD28− CD4+ T cells (Fig. 4c), in which 
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the AMPK-TAB1-p38 pathway is constitutively active (see above). Because TAB1 mediates 
p38 auto-phosphorylation20 (a modification that relies on the intrinsic activity of the kinase) 
and because p38 is not a direct substrate for AMPK, these data suggested that AMPK may 
induce p38 auto-phosphorylation via eliciting its binding to TAB1.
We therefore immunoprecipitated p38 from AMPK agonist-activated CD27+ CD28+ CD4+ 
T cells that were transduced with either shTAB1 or shAMPKα and assessed the kinase 
activity of p38 in the absence of an added substrate in vitro (e.g. to determine p38 auto-
phosphorylation14, 18). Using this assay, we detected activated p38 in immunoprecipitates 
from scrambled control-transduced CD27+ CD28+ CD4+ T cells, and this activity was 
enhanced by the addition of ATP in vitro. Conversely, adding ATP to p38 
immunoprecipitates from shTAB1 or shAMPKα-transduced CD27+ CD28+ CD4+ T cells 
did not increase p38 activity in vitro (Fig. 4d). This indicates that p38 auto-phosphorylation 
requires both AMPK-TAB1 with which p38 interacts in response to AMPK activation.
To confirm that the above experiment was indicative of p38 auto-phosphorylation (and not 
an event mediated by an unrelated co-immunoprecipitated kinase), we added the ATP-
competitor SB-203580, which acts as an inhibitor of p38, directly to the in vitro kinase 
reaction itself. SB-203580 prevented the enhanced p38 phosphorylation in vitro in response 
to exogenous ATP (but not the baseline kinase activation within the cells) in TAB1 
immunoprecipitates after AMPK activation (Fig. 4e). Similar results were obtained with a 
different inhibitor of p38 activity (BIRB 796, data not shown). Thus, the p38 recruited at the 
AMPK-TAB1 complex auto-phosphorylates.
AMPK or TAB1 silencing restores proliferation in senescent T cells
Loss of telomerase activity in senescent T cells3, 8, 15 limits their proliferative potential after 
antigenic challenge both in vitro and in vivo31, 32 and is mediated in part by p38 activation, 
as shown by rescue with a selective p38 small molecule inhibitor9, 33. To test whether TAB1 
or AMPKα silencing restored these functions in senescent T cells, we transduced activated, 
purified CD27− CD28− CD4+ T cells with the shAMPKα and shTAB1 lentiviral vectors 
(Supplementary Fig. 4a). Because telomerase activity in T lymphocytes specifically requires 
re-expression of the related catalytic subunit (hTERT) upon activation34, we measured 
hTERT expression by both immunoblot and quantitative PCR. hTERT expression was 
significantly enhanced in both AMPKα and TAB1-silenced CD27− CD28− CD4+ T cells 
compared to scrambled control-transduced cells, one week after activation with anti-CD3 
and rh-IL-2 (p< 0,01; Fig. 5a), leading to increased telomerase activity in these cells at the 
one week time point, as assessed by TRAP assay (Fig. 5b).
To assess the in vivo effect of enhanced telomerase activity in TAB1- or AMPKα– silenced 
CD27− CD28− CD4+ T cells, we measured telomere length by fluorescence in situ 
hybridization coupled to flow cytometry (flow-FISH), as described15. Four weeks after 
lentiviral vector transduction (Supplementary Fig. 4a), TAB1 or AMPKα knockdown 
induced a significant extension (0.5-0.7 kb) of telomeric length in the GFP+ CD27− CD28− 
CD4+ T cells compared to scrambled control cells (p< 0.001; Fig. 5c,d). Furthermore, the 
silencing of either TAB1 or AMPKα significantly enhanced the short-term proliferation of 
CD27− CD28− CD4+ T cells following activation with anti-CD3 and rh-IL-2 for 7 days, as 
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assessed by either thymidine incorporation (to assess de novo DNA synthesis) or dye 
dilution analysis (p< 0.01; Fig. 5e,f,g) as well as their long-term expansion capacity (30 
days in culture) compared to scrambled control (Fig. 5h). As a control, inhibition of p38 by 
shP38 or by blocking with two different specific inhibitors (BIRB 796 or SB203580) 
resulted in enhanced telomerase activity and short and long-term proliferation of senescent T 
cells (Supplementary Fig. 4b-g and data not shown), confirming previous studies9. Thus, the 
defective proliferation and telomerase activity of human senescent T cells can be reversed 
by the inhibition of AMPK and TAB1 upstream of p38.
To further dissect the role of p38 activation in the proliferation of human senescent T cells, 
we investigated the impact of p38 on the cell-cycle machinery. Because p38 blockade 
increased the rate of DNA synthesis (an event that characterizes actively S-phase cycling 
cells), we investigated the expression of several G1/S transition regulators in CD27− CD28− 
CD4+ T cells activated with anti-CD3 and rh-IL-2. Inhibition of p38 induced the coordinated 
down-modulation of cell-cycle inhibitors (p27, p21), up-regulation of D cyclins, enhanced 
Rb inactivation (by lowering the expression of active, under-phosphorylated Rb) and 
dampened activation of the tumour suppressor p53 that are all well-established events that 
promote the G1/S transition35 (Supplementary Fig. 5 and data not shown). Similar results 
were also obtained when tuning p38 activity by silencing AMPK or TAB1 with shRNAs in 
CD27− CD28− CD4+ T cells (data not shown), indicating that p38 activation induced by 
AMPK-TAB1 signaling inhibits cell-cycle progression at the G1/S checkpoint. These data 
suggest that AMPK-TAB1 activated p38 inhibits T cell proliferation by direct inhibition of 
cyclins, induction of cyclin inhibitors and downstream activation of p53.
p38 activation induces senescence characteristics in non-senescent T cells
To further link the AMPK-TAB1 pathway with p38 spontaneous activation, we activated 
non-senescent CD27+ CD28+ CD4+ T cells with the AMPK agonist A-769662 either in the 
presence or absence of the selective p38 inhibitor BIRB 796. A-769662 inhibited the 
telomerase activity, proliferation and expansion of CD27+ CD28+ CD4+ T cells activated 
with anti-CD3 and CD28 antibodies, while addition of BIRB 796 restored these functions 
(Fig. 6a,b and data not shown). Similar results were obtained in p38-silenced CD27+ CD28+ 
CD4+ T cells (Supplementary Fig. 6a,b). All these observations were reproduced in glucose 
starved CD27+ CD28+ CD4+ T cells, and they were counteracted in part by p38 inhibition 
(Supplementary Fig. 6c-e). However, cells did not survive the prolonged absence of glucose 
after 5 days (data not shown)36. In addition, AMPK activation by the A-769662 agonist 
induced a dose-dependent loss of TCR signaling molecules in CD27+ CD28+ CD4+ T cells 
activated with anti-CD3 and CD28 antibodies (Fig. 6c and data not shown), and this was in 
part prevented by p38 inhibition (Fig. 6d). Taken together, these data show that AMPK 
inhibits human T cell proliferation and telomerase via activation of p38, a process that 
requires its allosteric binding to TAB1. Furthermore non-senescent T cells activate p38 and 
downregulate proliferation and telomerase activity if AMPK is activated chemically or by 
glucose starvation.
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Discussion
In this study we investigated the mechanism of p38 activation in senescent human CD4+ T 
cells. In T cells, p38 activation was previously documented to be induced either by the 
canonical MAPK cascade or the alternative TCR signaling pathway in response to 
environmental stress or TCR activation respectively10, 11, 19. Here we have shown that 
senescent human CD4+ T cells lack essential ‘upstream’ components of both the canonical 
and the alternative pathways and instead activate p38 by a previously unrecognized AMPK-
TAB1-dependent mechanism. This occurs in vivo in response to endogenous DNA damage 
response (DDR) signaling by the apical kinase ATM, in response to genotoxic stress. 
However, glucose starvation can also trigger the energy gauge AMPK and lead to p38 
activation via the scaffold TAB1 in non-senescent CD4+ T cells that have no DNA damage. 
Therefore, signaling through this AMPK-TAB1 pathway for p38 activation can be induced 
in undifferentiated T cells by low nutrient availability or in senescent T cells by DNA 
damage. This leads to the down-regulation of key signaling molecules of the TCR complex 
and inhibition of both telomerase activity and proliferation.
The scaffold molecule TAB1 was initially identified as a TAK1 binding partner37. 
Subsequently, it was found that TAB1 could also induce allosteric p38 auto-phosphorylation 
in the human embryonic kidney 293 cell line, independently of TAK1(20, 21). However the 
biological relevance of TAB1-dependent p38 activation has remained uncertain. In a model 
of mouse ischemic cardiomyocytes, both TAB1 and AMPK were reported to act upstream of 
p38(22), but two subsequent studies in the same experimental system challenged the former 
report38, 39. The reason for the evolution of different modes of P38 MAPK activation are 
unknown, but our findings suggest that they may enable the same signaling molecule to 
exert opposite effects on T cell function. For example, we confirmed previous observations 
that ‘alternative’ DLG-mediated p38 activation downstream of the TCR supports 
proliferative activity in non-senescent CD4+ T cells17, however, p38 activated via AMPK-
TAB1 inhibits proliferation in both senescent and non-senescent human CD4+ T cells. 
Furthermore a recent report showed that ‘canonical’ and ‘alternative’ activated p38 counter-
regulate each other in controlling T cell effector functions by exerting different substrate 
specificity40. Also, we note that the mapped TAB1-p38 interaction site41 impedes access to 
the ‘alternative’ Y323 regulatory phosphorylation site of p38, suggesting that scaffold 
molecules may also be involved in the determination of downstream substrate specificity.
One unexpected observation was that key components of the TCR signaling machinery such 
as LCK, ZAP-70, DLG1, LAT and SLP-76 are naturally lost in senescent CD4+ T cells, 
which also loose CD27 and CD28 expression (8,35). The collective loss of these signaling 
molecules will exacerbate the inhibition of proliferation in these cells by decreasing their 
capacity for TCR activation. Of note, blocking p38 in highly differentiated T cells did not 
restore expression of the TCR signalosome (data not shown), suggesting that other p38 
independent mechanisms are involved.
At present, a number of p38 inhibitors have been developed for use in treating diseases with 
inflammatory aetiology42. When tested in clinical trials, those compounds showed low 
therapeutic index and engagement of escape or bypass mechanisms, this latter being 
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possibly due to the regulation of diverse cellular functions by p38 activation42. Because 
inhibition of p38 activity by silencing AMPK or TAB1 in vitro enhances human T cell 
proliferation we suggest the possibility of specific inhibition of this pathway as a strategy for 
enhancing immune cell function in vivo. The crystal structure of the docking site between 
TAB1 and p38 has been described41 and is conserved in both the 60-kDA and 50-kDA 
variants of this molecule21. Targeting of this restricted, MKK independent interaction may 
provide a selective way for dampening p38 activity as it would spare ubiquitous activation 
by the MAPK cascade10. One caveat is that the enhancement of telomerase and proliferation 
in highly differentiated T cells that have evidence of DNA damage may be tumorigenic35. 
The risk versus possible benefit of selective therapeutic tuning of telomerase in human T 
lymphocytes in vivo remains to be determined.
We have therefore described an ‘intra-sensory’ pathway in T cells that integrates nutrient 
and DNA damage sensing signals to activate p38. This may be the prototype of a number of 
convergent signaling pathways linking senescence, immune-modulation, metabolism and 
cancer. It is possible that AMPK/TAB1 signaling may be involved with p38 activation that 
is associated in the senescence of different cell types such as fibroblasts and cardiomyocytes 
in both mice and humans43,44 and this requires further study.
Methods
Cells
Heparinized peripheral blood samples were taken from healthy volunteers (aged 40-65, 
median 52, male 55% and female 45%; n=57). All samples were obtained with the approval 
of the Ethical Committee of Royal Free and University College Medical School and 
voluntary informed consent was obtained in accordance with the Declaration of Helsinki. 
Donors did not have any co-morbidity, were not on any immunosuppressive drugs, and 
retained physical mobility and lifestyle independence. The CD4+ CD27/CD28 defined 
subsets were isolated from peripheral blood mononuclear cells (PBMC) as previously 
described15.
Western Blot analysis
Purified CD4+ CD27/CD28 subsets were harvested ex vivo immediately after separation. 
Alternatively, purified human highly differentiated CD4+ CD27− CD28− T cells were 
harvested four days post transduction (see below). Lysates from 2 × 106 cells were obtained 
and analyzed as previously described33. Membranes were probed with anti-p38, MKK3, 
MKK6, phospho-MKK3/6 (Ser189/Ser207; 22A8), Lck, Zap70 (99F2), TAB1 (C25E9), 
TAK1, TRAF6 (D21G3), phospho-AMPKα (Thr172), AMPKα, phospho-γH2A-x (Ser139), 
Lat, SLP-76, PLC-γ 1, GAPDH (14C10) all from Cell Signalling. Anti-phospho-p38 
(Tyr323) was from ECM-Biosciences. hTERT (H-231) and DLG1 (SAP-97, 2D11) 
antibodies were from Santa Cruz Biotechnology. All immunoblots were developed using the 
ECL Prime Western Blotting Detection Kit (GE Healthcare), according to the 
manufacturer’s instructions.
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Immunoprecipitation
For co-immunoprecipitation analysis, cell-lysates were prepared using ice-cold HNGT 
buffer (50 mM HEPES, pH 7.5, 150 mM EDTA, 10 mM sodium pyrophosphate, 100 mM 
sodium orthovanadate, 100 mM sodium fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 
and 1 mM phenylmethylsulfonyl fluoride). Lysates from 20 × 106 purified primary human 
CD4+ CD27+ CD28+ T cells were incubated with monoclonal antibody to TAB1 or p38 
(Cell Signalling) at 4 °C on a rotary shaker overnight. For the minor CD4+ CD28− CD27− 
subset, cells from two separate individuals were pooled to obtain sufficient cells for analysis. 
Extracts were then incubated with protein A–G conjugated agarose beads (Santa Cruz 
Biotechnology) at 4 °C for 3 h. Samples were washed and analyzed by western blotting as 
indicated. Co-immunoprecipitated proteins were detected using Mouse Anti-rabbit IgG 
Conformation Specific (L27A9; Cell Signalling) or Mouse Anti-rabbit IgG light chain, 
followed by a secondary anti-mouse IgG antibody (all from Cell Signalling) and ECL Prime 
Western detection kit (GE Healthcare).
In vitro kinase assay
TAB1 or p38 immunoprecipitates were obtained as above described. Samples were washed 
twice in lysis buffer and twice in kinase buffer (all from Cell Signaling). Kinase reactions 
were incubated for 30 min at 30 °C in a the presence or absence of 200 μM ATP (Cell 
Signaling). In some experiments the ATP competitor p38 inhibitor SB-203580 (10 μM) was 
added directly to the in vitro kinase reaction, as indicated. Total p38 and phosphorylated p38 
(Thr180-Tyr182) levels were detected using the PhosphoTracer ELISA Kit according to the 
manufacturer’s instructions (Abcam). In vitro kinase assays are shown as proportional to 
fold increase at 450 nm absorbance emission of triplicate wells ± s.e.m.
Detection of intracellular ROS levels and calcium flux
Following surface staining for CD27 and CD28 receptors, human CD4+ T cells were 
incubated for intracellular ROS or Calcium levels with either Dihydroethidium (DHE) or 
Fluo-4 AM respectively, according to the manufacturer’s instructions (Invitrogen Molecular 
Probes). Cells were analyzed by flow-cytometry using an LSR Fortessa (BD Biosciences).
Lentiviral vector design
We generated the pHIV1-SIREN-GFP system used for knockdown of gene expression as 
follows. The pSIN-GFP lentivector45 was digested with EcoRI and BamHI, and the PGK 
promoter was amplified by polymerase chain reaction (PCR) introducing EcoRI-BamHI 
restriction sites. Then, the SFFV promoter from pSIN-GFP plasmid was replaced with the 
PGK promoter, cloned by blunt-ligation, to generate the pSIN-PGKp-GFP plasmid. This 
vector was used as a backbone. A cassette containing the human U6 promoter was cloned in 
this backbone downstream the cPPT sequence between ClaI-EcoRI restriction sites (see 
extended vector map, Fig. S2A). A BamHI site was introduced downstream of the U6 
promoter to clone the shRNAs of interest between BamHI and EcoRI restriction sites. The 
U6-shRNA cassette was placed upstream the PGK promoter and GFP. All constructs were 
engineered by standard cloning techniques.
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The following siRNA sequences were used for gene knockdowns: 
CCTAAGGTTAAGTCGCCCTCG (shCTRL), GGCGGTCCTTCTCAACAACAAG 
(shTAB1) and ATGATGTCAGATGGTGAATTT (shAMPKα) as described 
previously21,46,47. The siRNA sequence used for TAB1 knock-down targets a region which 
is common to both the 60 and 50 kDA isoforms of this molecule. The siRNA target used for 
p38 knockdown (shP38) was GTACTTCCTGTGTACTCTTTA. VSV-g pseudotyped 
lentiviral particles, were produced by transient co-transfection of three plasmids in HEK 293 
cells as previously described38 and concentrated 100-fold by ultracentrifugation through a 
20% sucrose cushion in phosphate-buffered saline (PBS), following re-suspension in PBS 
containing 10% glycerol. Lentiviral preparations were then titrated for GFP expression using 
serial dilutions in HEK 293 cells by flow cytometry.
Cell cultures and lentiviral transduction of primary human T lymphocytes
Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 
100 U/ml penicillin, 100 mg/ml streptomycin, 50 μg/ml gentamicin, and 2 mM L-glutamine 
(all from Invitrogen) at 37°C in a humidified 5% CO2 incubator. Purified human highly 
differentiated CD4+ CD27− CD28− T cells were activated in the presence of plate-bound 
αCD3 Ab (purified OKT3, 0.5 μg/ml) plus rhIL-2 (R&D Systems, 10 ng/ml), and then 
transduced with pHIV1-Siren lentiviral particles (MOI=10) at 48 and 72 hours after 
activation. For long-term cultures, transduced cells were re-activated every 10 days. 
Relatively undifferentiated CD4+ CD27+ CD28+ T cells were cultured and transduced as per 
CD4+ CD27− CD28− cells, but cells were activated by plate-bound αCD3 (0.5μg/mL) plus 
αCD28 (0.5 μg/mL).
Quantitative PCR (Real time analysis)
Four days post transduction, samples from 5 × 105 viable highly differentiated CD4+ CD27− 
CD28− T cells were resuspended in TRIzol (Ambion). For cDNA synthesis, RNA was retro-
transcribed using M-MuLV Reverse Transcriptase (New England Biolab) and random 
primers. P38, AMPKα, TAB1 and hTERT expression was detected by qPCR. Relative 
transcript expression was normalized against housekeeping GAPDH using the ΔΔCT 
threshold cycle method according to the supplier’s protocol (Applied Biosystems).
Signaling studies
Briefly, cells were fixed with warm Cytofix Buffer (BD Biosciences) at 37°C for 10 min. 
Cells were then permeabilized with ice-cold Perm Buffer III (BD Biosciences) at 4°C for 30 
min and incubated with antibodies to phospho-p38 (PE; Thr180/Tyr182), γ-H2AX (PE; 
Ser139), under-phosphorylated Rb, phosphorylated Rb (Ser807/Ser811) (all from BD 
Biosciences) or phospho-AMPKα (Thr172), phospho-ATM (Ser1921), phospho-ATF2 
(Thr71), phospho-p53 (Ser46), cyclin D1 and p27 (all from Cell Signaling), for 30 min at 
room temperature. Primary unconjugated antibodies were subsequently probed with a 
secondary mouse (or goat) PE-conjugated anti-rabbit IgG (BD Biosciences) for 30′ at room 
temperature, in the dark. Cells were washed in Stain Buffer (BD Pharmingen) and 
immediately run using an LSR Fortessa (BD Biosciences). In some experiments cells were 
pre-incubated with the AMPK agonist A-769662 (Tocris Bioscience, 150 μM, 60′), the 
ATM inhibitor KU-55933 (Calbiochem, 10 μM, 60′) or PMA (Sigma, 20 ng/mL) before 
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fixing, as indicated (see text). Data analysis was performed using FlowJo software 
(Treestar). For signaling studies using transduced cells, events were gated on the GFP+ 
compartment as indicated.
Measurement of telomerase activity
Telomerase activity was determined using the TeloTAGGG telomerase ELISA kit from 
Roche according to the manufacturer’s instructions from extracts of 2 × 103 viable 
transduced CD4+ CD27− CD28− T cells. The absolute numbers of CD4+ CD27− CD28− T 
cells were enumerated by trypan blue (Sigma) and Ki67 analysis, as previously described33. 
Telomerase activity is expressed as proportional to fold increase at 450nm absorbance 
emission of triplicate wells ± s.e.m.
Assessment of Telomere length
Telomere length of transduced CD27− CD28− CD4+ T cells was measured after 30 days of 
activation in culture, using a modified version of the flow-FISH method that was previously 
described15. Telomere length of transduced GFP+ CD4+ CD27− CD28− T cells is shown as 
the bp variation (delta, Δ) of GFP+ AMPKα or TAB1 silenced cells over an irrelevant 
scrambled control GFP+ CD4+ CD27− CD28− population.
Proliferation assays
Four days post transduction, proliferation of activated CD27-CD28− or CD27+ CD28+ CD4+ 
T cells was assessed by overnight probing with [3H] thymidine. Short-term proliferative 
activity is expressed as fold increase in [3H] thymidine incorporation (cpm) of triplicate 
wells ± s.e.m. Alternatively, purified human highly differentiated CD27− CD28− CD4+ T 
cells were immediately stained with CellTrace Violet Cell Proliferation Kit and analyzed by 
flow cytometry 96 hours post-transduction (day 7), according to the manufacturer’s 
instructions (Invitrogen). In some experiments using early differentiated CD27+ CD28+ 
CD4+ T cells, proliferation was assessed by staining for the cell cycle related nuclear antigen 
Ki67 following 48 hour activation, as described previously32. Population doubling levels 
(PDLs) were calculated as log10 (number of cells counted after expansion) – log10 (number 
of cells seeded)/log10 2.
Statistical analysis
Graphpad Prism was used to perform statistical analysis. For pairwise comparisons, a paired 
Student’s t test was used. For three matched groups, a one-way analysis of variance 
(ANOVA) for repeated measures using a Bonferroni posttest correction was used. 
Differences were considered significant when P was < 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Spontaneous p38 activation in the absence of both upstream canonical and alternative 
pathways in highly differentiated T cells
(a) The co-expression of CD27 and CD28 receptors by human CD4+ T cells, representative 
staining (n=9). (b) Phospho-flow data of spontaneous p38 (Thr180,Tyr182) phosphorylation 
in CD4+ CD27/CD28 defined subsets from 9 different donors (MFI, mean fluorescence 
intensity). (c) Immunoblots of total MKK3, MKK6 and phospho-MKK3/MKK6 
(Ser189,Ser206) in CD4+ CD27/CD28 defined subsets. GAPDH was used as a loading 
control. Data are representative of 4 independent experiments. (d) The relative level of 
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endogenous MKK3/6 activation vs. total GAPDH in CD4+ CD27/CD28 defined subsets of 4 
separate individuals. (e) Representative overlay and (f) pooled phospho-flow data from 3 
independent experiments showing p38 (Thr180,Tyr182) phosphorylation in CD27− CD28− 
and CD27+ CD28+ CD4+ T cells either before or after treatment with PMA (20 ng/mL, 60′). 
(g) Immunoblots of total p38 and phospho-p38 (Tyr323) in isolated CD27− CD28− and 
CD27+ CD28+ CD4+ T cells either before or after αCD3 activation (10 μg/mL, 30′). Data 
are representative of 3 independent experiments. (h) Representative blots of total Lck, 
Zap70 and DLG1 expression in CD4+ CD27/CD28 defined subsets; GAPDH was used as a 
loading control. Two different donors from the same gel are shown. (i) The relative level of 
Lck, Zap70 and DLG1 protein expression vs. total GAPDH in CD4+ CD27/CD28 defined 
subsets of 4 different subjects. All *p< 0,05, **p<0.01, and ***p< 0.001 values were 
calculated using one-way analysis of variance (ANOVA) for repeated-measures with a 
Bonferroni post-test correction. Error bars depict s.e.m.
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Figure 2. Spontaneous p38 activation triggered by AMPK and mediated by TAB1 in highly 
differentiated T cells
(a) Immunoblots of TAB1 (alternative isoforms depicted by black arrows), TAK1 and 
TRAF6 expression from 2 different subjects within the same gel and (b) total AMPKα and 
phospho-AMPKα (Thr172) expression in freshly isolated CD4+ CD27/CD28 defined 
subsets. Data are representative of (a) 4 or (b) 3 different donors. (c) Representative overlay 
and (d) pooled data from 3 separate experiments showing the effect of the AMPK activator 
A-769662 (150 μM, 60′) on p38 (Thr180,Tyr182) phosphorylation in CD27+ CD28+ CD4+ T 
cells as determined by phospho-flow analysis. (e) Representative FACS plot (n=9) showing 
expression of the reporter GFP gene in transduced purified CD27−CD28− CD4+ T cells, 96 
hours post transduction (left); overlay from the same experiment (middle) and pooled 
phospho-flow data from 3 separate experiments (right) showing steady-state p38 
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(Thr180,Tyr182) phosphorylation within the reporter GFP+ populations of CD27−CD28− 
CD4+ T cells transduced with lentiviral vectors encoding either shAMPKα, shTAB1 or 
shCtrl (knock-down validation in Supplementary Fig. 2). (f) Representative overlay and (g) 
pooled data from 3 separate experiments showing the effect of the AMPK activator 
A-769662 (150 μM, 60′) on p38 (Thr180,Tyr182) phosphorylation in CD27− CD28− CD4+ T 
cells transduced as indicated and analyzed within the GFP+ subsets by phospho-flow. (h) 
Representative overlay and (i) pooled phospho-flow data of ATF2 (Thr71) phosphorylation 
from 3 separate experiments performed as described in (f,g). In (d) a paired Student’s t test 
was used. For all other statistics a one-way analysis of variance (ANOVA) for repeated-
measures with a Bonferroni post-test correction. p< 0,05, **p<0.01, and ***p< 0.001. Error 
bars depict s.e.m.
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Figure 3. DNA damage and low-nutrient signals converge at AMPK which drives TAB1 
dependent p38 activation in T cells
(a) Representative overlay and (b) pooled phospho-flow data from 4 different subjects of 
spontaneous ATM (Ser1921) phosphorylation in CD27−CD28− and CD27+ CD28+ CD4+ T 
cells, directly ex vivo. (c) Immunoblot and (d) pooled phospho-flow data from 4 different 
subjects of γH2AX (Ser139) phosphorylation in freshly isolated CD4+ CD27/CD28 defined 
subsets; GAPDH served as loading control in (c). Immunoblot is representative of 2 
independent experiments. (e) Representative overlay and (f) pooled phospho-flow data 
showing the effect of the selective ATM inhibitor KU-55933 (60′, 10 μM) on constitutive 
AMPKα (Thr172) phosphorylation in CD27− CD28− CD4+ T cells. (g) Representative 
overlay and (h) pooled phospho-flow data of p38 (Thr180,Tyr182) phosphorylation from 3 
separate experiments performed as described in (e,f). (i) Representative overlay and (j) 
pooled results from 3 separate experiments showing the effect of 18 hours of glucose 
starvation on p38 (Thr180,Tyr182) phosphorylation in CD27+ CD28+ CD4+ T cells. (k) 
Representative overlay and (l) pooled data showing the effect of 18 hours glucose starvation 
on p38 (Thr180,Tyr182) phosphorylation in CD27+ CD28+ CD4+ T cells transduced as 
indicated and analyzed within the GFP+ subsets by phospho-flow.
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Figure 4. AMPK triggered p38 recruitment to TAB1 causes p38 auto-phosphorylation
(a) Immunoblots of total p38, phospho-p38 (Thr180,Tyr182), total AMPKα phospho-
AMPKα (Thr172) and TAB1 in CD27+ CD28+ CD4+ T cells activated with DMSO control 
or the AMPK agonist A-769662 (150 μM) for 2 hours, followed by immunoprecipitation 
with anti-TAB1. Data are representative of 4 separate donors. Immunoblot of total p38 from 
whole cell lysate (WCL) served as input control. (b) The relative binding of p38 to TAB1 
upon AMPK activation as determined by 4 independent experiments performed as described 
in (a). (c) Freshly-isolated CD27+ CD28+ or CD27− CD28− CD4+ T cells were 
immunoprecipitated with anti-TAB1 and analyzed by immunoblot, as indicated (alternative 
TAB1 isoforms depicted by black arrows). Data are representative of 2 separate experiments 
(for the minor CD4+ CD27− CD28− T cell fraction, cells were pooled together from 2 
different donors to achieve sufficient cell number to perform the assay). (d) Measurement of 
p38 auto-phosphorylation by ELISA-based in vitro kinase assay of p38 immunoprecipitates 
from transduced purified CD27+ CD28+ CD4+ T cells reactivated with the AMPK agonist 
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A-769662 (150 μM) for 2 hours. Immunoprecipitates were left untreated or incubated for 30 
min with ATP (200 μM). (e) Measurement of p38 auto-phosphorylation of TAB1 
immunoprecipitates from CD4+ CD27+ CD28+ T cells activated with the AMPK agonist 
A-769662 (150 μM) for 2 hours. The assay was performed as described in (d) in the 
presence or absence of the p38 inhibitor SB-203580 (10 μM). Experiments in (d,e) were 
perfomed from 3 different donors. In (b) a paired Student’s t test was used; for (d) and (e) a 
one-way analysis of variance (ANOVA) for repeated-measures with a Bonferroni post-test 
correction. *p< 0,05, **p<0.01, and ***p< 0.001. Error bars depict s.e.m.
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Figure 5. Silencing of AMPK or TAB1 restores telomerase and proliferation in highly 
differentiated T cells
(a) Measurement of hTERT expression by both immunoblot (left) and quantitative PCR 
(right) in CD27− CD28− CD4+ T cells, transduced as indicated and analyzed 96 hours later 
(see also Supplementary Fig. 4a). Immunoblot of hTERT expression is representative of 2 
independent experiments; samples for quantitative PCR are from 3 different donors and 
normalized against housekeeping GAPDH expression. (b) Telomerase activity by TRAP 
assay in CD27− CD28− CD4+ T cells transduced and cultured as described in (a). Data are 
from 3 separate donors. (c) Representative overlay and (d) the pooled flow-fish data from 3 
separate experiments showing telomere elongation in both shAMPKα and shTAB1 
transduced GFP+ CD27− CD28− CD4+ T cells vs the shCtrl GFP+ population. Telomere 
length was measured after 2 rounds of activation in culture (day 30; see also Supplementary 
Fig. 4a). (e-f) Proliferative activity by (e) [3H] thymidine incorporation assay (n=3) or (f) 
dye dilution analysis in CD27− CD28− CD4+ T cells transduced as indicated and analyzed 
96 hours later. (g) The pooled results of 3 separate experiments performed as in (f). (h) 
Replicative lifespan by cumulative PD of long-term cultured CD27− CD28− CD4+ T cells, 
transduced as indicated (see also Supplementary Fig. 4a). Data are from 3 separate donors. 
All *p< 0,05, **p<0.01, and ***p< 0.001 values were calculated using a one-way analysis 
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of variance (ANOVA) for repeated-measures with a Bonferroni post-test correction. Error 
bars depict s.e.m.
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Figure 6. p38 activation by a specific AMPK agonist reproduces senescent features in non-
senescent T cells
(a) Telomerase activity by TRAP assay in CD27+ CD28+ CD4+ T cells activated by αCD3/
CD28 and cultured as indicated for 3 days. AMPK was activated by A-769662 (150 μM); 
p38 was inhibited by BIRB 796 (500 nM). A DMSO vehicle solution was used as control. 
Experiments are from 3 different donors. (b) Replicative lifespan of long-term cultured 
CD27+ CD28+ CD4+ T cells assessed by cumulative PD from 3 separate donors. Cells were 
activated and cultured as described in (a). (c) Immunoblots showing the dose-dependent 
effect of the AMPK agonist A-769662 (0, 100 or 150 μM) on total Lck, Zap70 and SLP-76 
expression, after 3 days, in CD27+ CD28+ CD4+ T cells activated by αCD3/CD28. A 
DMSO vehicle solution was used as control; detection of AMPKα 172) phosphorylation 
served as pharmacological activation control. Immunoblots are representative of 4 
independent experiments. (d) Pooled phospho-flow data from 3 independent experiments 
showing Lat and SLP-76 expression in CD27+ CD28+ CD4+ T cells cultured as described in 
(a-b) for 3 days. All *p< 0,05, **p<0.01, and ***p< 0.001 values were calculated using a 
one-way analysis of variance (ANOVA) for repeated-measures with a Bonferroni post-test 
correction. Error bars depict s.e.m.
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